Who are Cefadroxil discontinued early's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): CEPHALEXIN, Cefazolin 2 GM Injection, Cefadroxil tablets manufactured by NP, Cefadroxil until drain removal, Cefadroxil tablets manufactured by GSK, CREXONT ER.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cefadroxil-discontinued-early.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Cefadroxil discontinued early — Competitive Intelligence Brief

Cefadroxil discontinued early (Cefadroxil discontinued early) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: First-generation cephalosporin. Area: Infectious Disease.

marketed First-generation cephalosporin Penicillin-binding proteins (PBPs) Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Cefadroxil discontinued early (Cefadroxil discontinued early) — Stony Brook University. Cefadroxil is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Cefadroxil discontinued early TARGET	Cefadroxil discontinued early	Stony Brook University	marketed	First-generation cephalosporin	Penicillin-binding proteins (PBPs)
CEPHALEXIN	CEPHALEXIN		marketed	First-generation cephalosporin	Penicillin-binding proteins (PBPs)	1971-01-01
Cefazolin 2 GM Injection	Cefazolin 2 GM Injection	Abdul El-Rabbany	marketed	First-generation cephalosporin	Penicillin-binding proteins (PBPs)
Cefadroxil tablets manufactured by NP	Cefadroxil tablets manufactured by NP	GlaxoSmithKline	marketed	First-generation cephalosporin	Penicillin-binding proteins (PBPs)
Cefadroxil until drain removal	Cefadroxil until drain removal	Stony Brook University	marketed	First-generation cephalosporin	Penicillin-binding proteins (PBPs)
Cefadroxil tablets manufactured by GSK	Cefadroxil tablets manufactured by GSK	GlaxoSmithKline	marketed	First-generation cephalosporin	Penicillin-binding proteins (PBPs)
CREXONT ER	CREXONT ER	Impax Laboratories, LLC	marketed	First-generation cephalosporin antibiotic	Penicillin-binding proteins (PBPs)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (First-generation cephalosporin class)

Aultman Health Foundation · 2 drugs in this class
GlaxoSmithKline · 2 drugs in this class
Stony Brook University · 2 drugs in this class
· 1 drug in this class
Abdul El-Rabbany · 1 drug in this class
University of Florida · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Cefadroxil discontinued early — Competitive Intelligence Brief. https://druglandscape.com/ci/cefadroxil-discontinued-early. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab